Emerging drugs and alternative possibilities in the treatment of tuberculosis.

about

Impact of Hypoxia on Drug Resistance and Growth Characteristics of Mycobacterium tuberculosis Clinical Isolates Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers.

P2860

Q28553487-D01D2607-2D8A-4CA1-A078-B7621CBDE742 Q30275673-59CF3647-24A6-4445-9FAA-154EDDC3C474

P2860

Emerging drugs and alternative possibilities in the treatment of tuberculosis.

Item

http://www.wikidata.org/entity/Q38724073

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Emerging drugs and alternative possibilities in the treatment of tuberculosis.

@en

type

Item

label

Emerging drugs and alternative possibilities in the treatment of tuberculosis.

@en

prefLabel

Emerging drugs and alternative possibilities in the treatment of tuberculosis.

@en

P1476

Emerging drugs and alternative possibilities in the treatment of tuberculosis.

@en

P2093

D Van Soolingen

http://www.w3.org/2001/XMLSchema#string

J W C Alffenaar

http://www.w3.org/2001/XMLSchema#string

M G G Sturkenboom

http://www.w3.org/2001/XMLSchema#string

M M Segers

http://www.w3.org/2001/XMLSchema#string

M S Bolhuis

http://www.w3.org/2001/XMLSchema#string

S Ghimire

http://www.w3.org/2001/XMLSchema#string

S Hofman

http://www.w3.org/2001/XMLSchema#string

P2860

Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis

Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB

Treatment and Outcome Analysis of 205 Patients with Multidrug-resistant Tuberculosis

Tuberculosis vaccines: beyond bacille Calmette-Guerin

Fluoroquinolones for treating tuberculosis

Bedaquiline: First FDA-approved tuberculosis drug in 40 years

Randomized, placebo-controlled Phase II trial of heat-killed Mycobacterium vaccae (Immodulon batch) formulated as an oral pill (V7)

Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines

Polyphasic taxonomic analysis establishes Mycobacterium indicus pranii as a distinct species

Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung

P304

103-116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728214.2016.1151000

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26848966

http://www.w3.org/2001/XMLSchema#string

Emerging drugs and alternative possibilities in the treatment of tuberculosis.

about

P2860

P2860

Emerging drugs and alternative possibilities in the treatment of tuberculosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698